Stockscreener 앱 받기
106.05
2.05%
-2.22
시간 외 거래:
106.25
0.20
+0.19%
전일 마감가:
$108.27
열려 있는:
$107.8
하루 거래량:
15.10M
Relative Volume:
2.02
시가총액:
$184.41B
수익:
$44.33B
순이익/손실:
$6.48B
주가수익비율:
28.64
EPS:
3.7033
순현금흐름:
$6.92B
1주 성능:
-12.16%
1개월 성능:
-15.05%
6개월 성능:
-16.07%
1년 성능:
-16.75%
1일 변동 폭
$105.27
$108.63
1주일 범위
$105.27
$114.00
52주 변동 폭
$105.27
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
106.05 | 188.27B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.79 | 138.83B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
357.83 | 135.60B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.79 | 129.09B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
81.86 | 48.51B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott CEO Signals Confidence with Major Share Purchase - AD HOC NEWS
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next - TechStock²
How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) - Yahoo Finance
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy - TechStock²
Babies Are Getting Sick From Formula That Mimics Mother’s Milk - Bloomberg.com
Here’s Why Abbott Stock Could Deliver 10% Upside in 2026 After 15% Decline Last Year - TIKR.com
Abbott stock fell the most in 23 years after earnings. The CEO bought $2 million of shares - MSN
Abbot (ABT) is a High Quality Company, Says Jim Cramer - Insider Monkey
Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. - Barron's
Abbott Laboratories Stock Now 19% Cheaper, Time To Buy - Trefis
What To Expect From Stryker’s (SYK) Q4 Earnings - TradingView
Is Abbott (ABT) Insider Buying Offsetting Concerns Around Nutrition and Diagnostics Earnings Pressure? - simplywall.st
Abbott Laboratories (NYSE:ABT) Finds Support After Recent S&P 500 Decline - Kalkine Media
Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits - MassDevice
Abbott executive who led TAVR, Tendyne divisions announces exit - Cardiovascular Business
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Lbp Am Sa Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Optimism around Abbott Laboratories (NYSE:ABT) delivering new earnings growth may be shrinking as stock declines 11% this past week - Yahoo Finance
ABT.SW Abbott Laboratories (SIX) CHF100 27 Jan 2026 volume spike: watch momentum - Meyka
Top Executive Makes Bold Move With Major Abbott Laboratories Stock Purchase - TipRanks
Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal - simplywall.st
Ill. Judge Trims False Ad Suit Over Abbott Formula - Law360
Evercore ISI says Abbott’s (ABT) core growth drivers are still intact - MSN
Abbott Laboratories (ABT) Rebounds After Recent Losses - GuruFocus
Abbott Laboratories snaps six straight sessions of losses - MSN
Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact - Insider Monkey
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Mala Gaonkar, Millennium Management, Berkshire Hathaway, Abbott Laboratories (ABT), GameStop Corp (GME), and More - Insider Monkey
Abbott Eterna Spinal Cord Stimulator Lawsuit Filed Over Lead Migration, Device Malfunction - AboutLawsuits.com
AtaCor Medical Teams Up with Abbott on Defibrillator - ocbj.com
Abbott Laboratories (ABT) CEO Increases Stake with $2M Stock Pur - GuruFocus
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Ford Robert B, Abbott Laboratories chairman, buys $2 million in ABT - Investing.com Nigeria
Ford Robert B buys Abbott shares worth $2m By Investing.com - Investing.com Nigeria
Mutual of America Capital Management LLC Sells 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
Abbott TAVR leader Chris Waddell is leaving the company - MassDevice
Abbott’s Pōkeno Entry Signals Strategic Nutrition Play - en.edairynews.com
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low - TechStock²
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy (NYSE:ABT) - Seeking Alpha
Sawgrass Asset Management LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Commerzbank Aktiengesellschaft FI Buys 20,825 Shares of Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Is Abbott's January pullback a good time to buy? - MSN
Is Abbott’s January Pullback a Good Time to Buy? - MarketBeat
Mn Services Vermogensbeheer B.V. Acquires 9,900 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Buys 44,239 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management - MarketBeat
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity - Seeking Alpha
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
2.08%
자본화:
|
볼륨(24시간):